NASDAQ:EPZM Epizyme Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.48 0.00 (0.00%) (As of 06/28/2022 12:00 AM ET) Add Compare Share Today's Range$1.46▼$1.4850-Day Range$0.42▼$1.4852-Week Range$0.41▼$9.51Volume10.53 million shsAverage Volume3.15 million shsMarket Capitalization$244.02 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EPZM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter. Email Address EPZM Stock Forecast (MarketRank)Overall MarketRank™2.49 out of 5 starsMedical Sector144th out of 1,433 stocksPharmaceutical Preparations Industry52nd out of 685 stocksAnalyst Opinion: 3.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 - 3.0 Analyst's Opinion Consensus RatingEpizyme has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Epizyme has a forecasted upside of 136.5% from its current price of $1.48.Amount of Analyst CoverageEpizyme has only been the subject of 4 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesEpizyme has received 477 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEpizyme has received 205 “underperform” votes. (Add your “underperform” vote.)Community SentimentEpizyme has received 69.94% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote “Outperform” if you believe EPZM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEpizyme does not currently pay a dividend.Dividend GrowthEpizyme does not have a long track record of dividend growth. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Epizyme insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,467.00 in company stock.Percentage Held by Insiders23.40% of the stock of Epizyme is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.45% of the stock of Epizyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Epizyme are expected to grow in the coming year, from ($1.38) to ($1.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Epizyme is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Epizyme is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Epizyme (NASDAQ:EPZM)Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More EPZM Stock News HeadlinesJune 29, 2022 | americanbankingnews.comCowen Lowers Epizyme (NASDAQ:EPZM) to Market PerformJune 29, 2022 | americanbankingnews.comCowen Downgrades Epizyme (NASDAQ:EPZM) to Market PerformJune 28, 2022 | lse.co.ukIN BRIEF: BioPharma Credit says Epizyme investment to be prepaid | Financial News - London South EastJune 27, 2022 | benzinga.comWedbush Downgrades Epizyme to Neutral - Benzinga - BenzingaJune 27, 2022 | businesswire.comEPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders - Business WireJune 27, 2022 | marketwatch.comEpizyme Shares Take Flight on Takeover by Ipsen >EPZM - MarketWatchJune 27, 2022 | finance.yahoo.comEpizyme shares soar 60% on acquisition newsJune 27, 2022 | nasdaq.comProsus, miners lift European shares to two-week high - NasdaqJune 27, 2022 | nasdaq.comEuropean Shares Set For Steady Opening As Inflation Worries Ease - NasdaqJune 27, 2022 | businesswire.comIpsen to Acquire Epizyme, Expanding Its Portfolio in Oncology - Business WireJune 18, 2022 | americanbankingnews.comEpizyme (NASDAQ:EPZM) Shares Pass Below Two Hundred Day Moving Average of $1.46June 9, 2022 | benzinga.comEpizyme's Return On Capital Employed Insights - Benzinga - BenzingaJune 9, 2022 | finance.yahoo.comWhy Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPZM CUSIPN/A CIK1571498 Webwww.epizyme.com Phone(617) 229-5872Fax617-349-0707Employees250Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today6/28/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$6.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+271.6%Consensus RatingHold Rating Score (0-4)2 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-251.12 million Net Margins-614.08% Pretax Margin-613.94% Return on Equity-2,459.33% Return on Assets-73.85% Debt Debt-to-Equity RatioN/A Current Ratio5.87 Quick Ratio5.75 Sales & Book Value Annual Sales$37.43 million Price / Sales6.52 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-2.74Miscellaneous Outstanding Shares164,875,000Free Float126,294,000Market Cap$244.02 million OptionableOptionable Beta1.30 Epizyme Frequently Asked Questions Should I buy or sell Epizyme stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Epizyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares. View analyst ratings for Epizyme or view top-rated stocks. What is Epizyme's stock price forecast for 2022? 5 Wall Street research analysts have issued 12-month target prices for Epizyme's shares. Their EPZM stock forecasts range from $1.50 to $6.00. On average, they expect Epizyme's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price. View analysts' price targets for Epizyme or view top-rated stocks among Wall Street analysts. How has Epizyme's stock performed in 2022? Epizyme's stock was trading at $2.50 on January 1st, 2022. Since then, EPZM stock has decreased by 40.8% and is now trading at $1.48. View the best growth stocks for 2022 here. When is Epizyme's next earnings date? Epizyme is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Epizyme. How were Epizyme's earnings last quarter? Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. The biopharmaceutical company earned $8.70 million during the quarter, compared to analysts' expectations of $10.86 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 614.08%. During the same quarter in the previous year, the firm earned ($0.69) EPS. View Epizyme's earnings history. Who are Epizyme's key executives? Epizyme's management team includes the following people: Mr. Grant C. Bogle, Pres, CEO, Principal Financial Officer & Director (Age 64, Pay $923.32k)Dr. Jeffery L. Kutok M.D., Ph.D., Chief Scientific Officer (Age 55, Pay $646.13k)Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory BoardDr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory BoardMr. Jerald Korn J.D., Chief Operating Officer (Age 43)Mr. Joseph Beaulieu, Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer (Age 41) (LinkedIn Profile)Mr. Craig West CFA, VP of Investor RelationsMr. John F. Weidenbruch, Sr. VP, Gen. Counsel & Sec. (Age 61)Ms. Tanja Weber, Chief Bus. OfficerDr. Mark A. De Rosch Ph.D., Chief Regulatory Officer (Age 58) Who are some of Epizyme's key competitors? Some companies that are related to Epizyme include Procaps Group (PROC), Avid Bioservices (CDMO), MannKind (MNKD), Crinetics Pharmaceuticals (CRNX), ImmunoGen (IMGN), Veru (VERU), Merus (MRUS), I-Mab (IMAB), Aclaris Therapeutics (ACRS), Enanta Pharmaceuticals (ENTA), Deciphera Pharmaceuticals (DCPH), uniQure (QURE), Rocket Pharmaceuticals (RCKT), ADVANZ PHARMA (CXRXF) and Morphic (MORF). View all of EPZM's competitors. What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX). What is Epizyme's stock symbol? Epizyme trades on the NASDAQ under the ticker symbol "EPZM." Who are Epizyme's major shareholders? Epizyme's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.44%), BlackRock Inc. (6.55%), Vanguard Group Inc. (4.53%), Rock Springs Capital Management LP (4.41%), Palo Alto Investors LP (4.12%) and Platinum Investment Management Ltd. (4.01%). Company insiders that own Epizyme stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal. View institutional ownership trends for Epizyme. Which institutional investors are selling Epizyme stock? EPZM stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Graham Capital Management L.P., BNP Paribas Arbitrage SA, State Board of Administration of Florida Retirement System, and Group One Trading L.P.. Company insiders that have sold Epizyme company stock in the last two years include Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal. View insider buying and selling activity for Epizyme or view top insider-selling stocks. Which institutional investors are buying Epizyme stock? EPZM stock was purchased by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Rock Springs Capital Management LP, BlackRock Inc., Assenagon Asset Management S.A., Goldman Sachs Group Inc., Bank of America Corp DE, Woodline Partners LP, and Vanguard Group Inc.. Company insiders that have bought Epizyme stock in the last two years include Carl Goldfischer, David M Mott, and Pablo G Legorreta. View insider buying and selling activity for Epizyme or or view top insider-buying stocks. How do I buy shares of Epizyme? Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Epizyme's stock price today? One share of EPZM stock can currently be purchased for approximately $1.48. How much money does Epizyme make? Epizyme (NASDAQ:EPZM) has a market capitalization of $244.02 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251.12 million in net income (profit) each year or ($2.14) on an earnings per share basis. How many employees does Epizyme have? Epizyme employs 250 workers across the globe. How can I contact Epizyme? Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for Epizyme is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at [email protected], or via fax at 617-349-0707. This page (NASDAQ:EPZM) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here